<DOC>
	<DOCNO>NCT00319332</DOCNO>
	<brief_summary>This multi-center , randomize , study compare Iodine I 131 Tositumomab therapeutic regimen Ibritumomab Tiuxetan therapeutic regimen treatment patient relapse transformed follicular non-Hodgkin 's B-cell lymphoma . A total 350 patient , approximately 175 patient per arm , enrol 30 40 site United States .</brief_summary>
	<brief_title>A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm diagnosis follicular lymphoma , Grade 1 , 2 , 3 , diffuse large cell lymphoma concurrent follow diagnosis follicular lymphoma ( WHO/REAL classification ) . International Working Formulation histological equivalent Follicular , small cleave ; Follicular , mixed smallcleaved largecell ; follicular largecell ; Transformed diffuse large cell lymphoma follow concurrent diagnosis follicular lymphoma . Patients diagnose diffuse large cell lymphoma study enrollment must historical contemporaneous lymph node biopsy demonstrate diagnosis follicular lymphoma . Recurrent lymphoma least three qualify therapy regimen include least one Rituximabcontaining regimen least one chemotherapy regimen . The patient must either respond respond duration response le 6 month Rituximabcontaining regimen , Performance status least 70 % Karnofsky Scale anticipate survival least three month . Bidimensionally measurable disease least one lesion measure 4.0 cm2 CT scan . Absolute neutrophil count &gt; /= 1500 cells/mm3 platelet count &gt; /=100,000/mm3 within 21 day prior study enrollment . Blood product and/or growth factor take within 4 week prior blood draw . Adequate renal function ( define serum creatinine &lt; 1.5 x upper limit normal ) adequate hepatic function ( defined total bilirubin &lt; 1.5x upper limit normal AST &lt; 5x upper limit normal ) within 21 day prior study enrollment . Human AntiMurine Antibody ( HAMA ) negative within 21 day prior study enrollment . Provision inform consent signify signed IRB approve consent form prior studyspecific procedure implement . Exclusion criterion : Greater 25 % intratrabecular marrow space involve lymphoma bone marrow biopsy specimen assess microscopically within 90 day prior study enrollment . Hypocellular bone marrow ( &lt; /=15 % cellularity mark reduction bone marrow precursor ) . Prior myeloablative therapy . History fail stem cell collection . Prior radiotherapy field encompass 25 % blood forming marrow . Prior chemotherapy , biologic therapy , radiation therapy steroid therapy NHL within eight week prior screen procedure . Prior radioimmunotherapy . Prior treatment nonhuman , particularly murine monoclonal polyclonal antibody either diagnostic therapeutic purpose . This exclusion extend chimeric monoclonal antibody , Rituximab . Prior malignancy lymphoma , except adequately treat basal cell squamous cell skin cancer , situ uterine cervical cancer , cancer patient diseasefree five year . Active infection require intravenous antibiotic time study enrollment . New York Heart Association Class III IV heart disease serious illness would preclude evaluation . HBsAg seropositivity . Known HIV infection . Known brain leptomeningeal metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>non-Hodgkin 's Lymphoma</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>BEXXAR</keyword>
	<keyword>ZEVALIN</keyword>
	<keyword>Iodine I 131 Tositumomab</keyword>
	<keyword>Ibritumomab Tiuxetan</keyword>
	<keyword>Follicular , mixed small-cleaved large-cell</keyword>
	<keyword>Diffuse large cell non-Hodgkin 's lymphoma follow concurrent diagnosis follicular lymphoma</keyword>
</DOC>